Federal judge allows Nexium reverse payment patent settlement suit to proceed
Last week, a federal judge in Massachusetts largely denied a series of motions seeking dismissal of various ‘pay-for-delay’ claims brought by direct and indirect purchasers involving AstraZeneca’s acid reflux drug Nexium. Although certain federal and state claims were trimmed on statute of limitation grounds, US district judge William Young let stand the core claims of the suit based on the alleged continuing harm flowing from the agreements.
This ruling comes just months after the Supreme Court’s long-awaited decision in FTC v Actavis and is one of the first times a court has applied the rule of reason analysis as articulated by the court. Significantly, in his ruling Young adopted a view strongly urged by the FTC that so-called ‘No-AG’ provisions can be viewed as ‘reverse payments’.
The agreements at issue settled patent litigation filed by AstraZeneca in November 2005 after Ranbaxy notified AstraZeneca that it intended to market generic versions of Nexium. As part of its Abbreviated New Drug Application (ANDA), Ranbaxy included a so-called ‘Paragraph IV’ certification that the commercial manufacture, use and/or sale of any generic Nexium product would not infringe any of AstraZeneca’s valid patents. The Ranbaxy ANDA filing was followed soon after by ANDA filings by Teva and Dr Reddy’s and additional patent suits filed by AstraZeneca against each…
If you are registered and logged in to the site, click on the link below to read the rest of the Hogan Lovells briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Hogan Lovells
News from The Lawyer
Briefings from Hogan Lovells
The decision of the US Court of Appeals has raised questions about how issuers should present their disclosures on conflict minerals under Exchange Act Rule 13p-1 and Form SD.
An interesting judgment was delivered by the Honourable J Majiki on 19 November 2013 in the Eastern Cape High Court, Port Elizabeth.
Analysis from The Lawyer
As international firms question their future in these small, closely linked markets, local lawyers too are eyeing the business environment with caution
Beyond the headline infrastructure projects, UK construction work is still recovering from the clobbering it took during the slump